Investors
-
March 18, 2024Umecrine Cognition will attend BIO-Europe Spring® 2024 in BarcelonaSTOCKHOLM – March 18, 2024. Umecrine Cognition today announces that the company will attend BIO-Europe Spring® in Barcelona, Spain. The meeting...
-
March 15, 2024Scientific review of golaxonolone’s therapeutic potential on symptoms arising from neuroinflammation published in Frontiers in PharmacologySTOCKHOLM – March 15, 2024. Umecrine Cognition today announces that the company has contributed to a review article outlining the scientific...
-
March 6, 2024Umecrine Cognition presents nonclinical data at AD/PD™ 2024 further elucidating golexanolone’s mode-of-action in Parkinson’s diseaseSTOCKHOLM – March 6, 2024. Umecrine Cognition today announces that the company will attend the 18th International Conference on Alzheimer’s and...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.